Kiniksa Pharmaceuticals (KNSA)
(Delayed Data from NSDQ)
$19.77 USD
-0.34 (-1.69%)
Updated May 17, 2024 04:00 PM ET
After-Market: $19.77 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth D Momentum D VGM
Brokerage Reports
Kiniksa Pharmaceuticals, Ltd. [KNSA]
Reports for Purchase
Showing records 21 - 40 ( 110 total )
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
ARCALYST Scores a Triple and Looks to Overseas Expansion
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
Highlights Pipeline Progress While We Await ARCALYST Updates
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
KNSA Drops ARDS but ARCALYST Remains the Value Driver
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
ARCALYST Bats Two for Two; Pipeline Progress on Point
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
ARCALYST Beats in Q2, Looking for Gold in Q3
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D